

1 Ultrafast RNA extraction-free SARS-CoV-2 detection by direct RT-
2 PCR using a rapid thermal cycling approach

3

4 Robin Struijk¹, Anton van den Ouden¹, Brian McNally¹, Theun de Groot², Bert Mulder² and Gert de
5 Vos^{1*}.

6 ¹Molecular Biology Systems B.V., Scottweg 1-09, 4462GS Goes, The Netherlands.

7 ²Department of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Ziekenhuis, Weg
8 door Jonkerbos 100, 6532 SZ Nijmegen, The Netherlands.

9 *Corresponding author; gertdevos@mbspcr.com

10

11 Abstract

12 The surging COVID19 pandemic has underlined the need for quick, sensitive, and high-throughput
13 SARS-CoV-2 detection assays. Although many different methods to detect SARS-CoV-2 particles in
14 clinical material have been developed, none of these assays are successful in combining all three of the
15 above characteristics into a single, easy-to-use method that is suitable for large-scale use. Here we report
16 the development of a direct RT-PCR SARS-CoV-2 detection method that can reliably detect minute
17 quantities of SARS-CoV-2 gRNA in nasopharyngeal swab samples as well as the presence of human
18 genomic DNA. An extraction-less validation protocol was carried out to determine performance
19 characteristics of the assay in both synthetic SARS-CoV-2 RNA as well as clinical specimens.
20 Feasibility of the assay and analytical sensitivity was first determined by testing a dilution series of
21 synthetic SARS-CoV-2 RNA in two different solvents (water and AMIES VTM), revealing a high
22 degree of linearity and robustness in fluorescence readouts. Following analytical performance using
23 synthetic RNA, the limit of detection was determined at equal to or less than 1 SARS-CoV-2 copy/ul
24 of sample in a commercially available sample panel that contains surrogate clinical samples with
25 varying SARS-CoV-2 viral load. Lastly, we benchmarked our method against a reference qPCR method
26 by testing 87 nasopharyngeal swab samples. The direct endpoint ultra-fast RT-PCR method exhibited
27 a positive percent agreement score of 98.5% and a negative percent agreement score of 100% as
28 compared to the reference method, while RT-PCR cycling was completed in 27 minutes/sample as
29 opposed to 60 minutes/sample in the reference qPCR method. In summary, we describe a rapid direct
30 RT-PCR method to detect SARS-CoV-2 material in clinical specimens which can be completed in
31 significantly less time as compared to conventional RT-PCR methods, making it an attractive option
32 for large-scale SARS-CoV-2 screening applications.

33 Introduction

34 At the end of 2019, a novel strain of betacoronavirus called 2019_nCoV was identified¹ in Wuhan,
35 Hubei Province, China. In the following months, the virus proved highly contagious and as of
36 September 20th, 2021, a total of 228,394,572 confirmed cases of COVID-19 including 4,690,186 deaths

37 have been reported according to the World Health Organization Coronavirus (COVID-19) Dashboard.
38 Shortly after its identification, 2019_nCoV was renamed to the current consensus² term SARS-CoV-2
39 and the first complete SARS-CoV-2 RNA sequence was made public by the Chinese Centers for
40 Disease Control and Prevention.

41 The emergence of SARS-CoV-2 has underlined the need for rapid and easy-to-implement diagnostic
42 nucleic acid detection methods. Nucleic acid amplifications tests (NAAT) such as multiplex reverse-
43 transcriptase polymerase chain reaction (RT-PCR) remain the test of choice³ for the detection of
44 respiratory viruses due to their sensitivity, specificity, and time to virus detection. According to the
45 CDC Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19 Testing,
46 nasopharyngeal swabs (NPS) are the preferred method to obtain biological samples for respiratory virus
47 detection.

48 In this study we describe a highly efficient direct reverse transcriptase PCR (RT-PCR) protocol using
49 our proprietary NextGenPCR ultra-fast thermocycler for the detection of SARS-CoV-2 genomic targets
50 in NPS that does not require RNA extraction. For example to analyze 90 (?) samples from sample to
51 result takes approximately 60 minutes with a total RT-PCR cycling time of 27 minutes. An input of
52 only $\leq 10\mu\text{l}$ of patient material dissolved in viral transport medium (VTM) such as AMIES liquid is
53 required to achieve a test result. Identification of SARS-CoV-2 positive and negative samples by end-
54 point NextGenPCR RT-PCR is highly accurate as compared to a reference qPCR method on extracted
55 RNA and, owing to its superior speed, is shown to be suitable for large-scale screening purposes where
56 time to detection is a crucial factor.

57 **Methods**

58 **Sample collection and preparation**

59 *Synthetic SARS-CoV-2 RNA*

60 Logarithmic dilution series were made by serial dilution of SARS-CoV-2 RNA Control #2 (directed at
61 the MN908947.3 viral RNA contingency [Wuhan-Hu-1 strain] Cat. no. #102024, Twist BioScience,
62 USA) in nuclease-free H₂O (cat. no. E476-500ML, VWR, Netherlands) or AMIES liquid (cat. no.

63 K737B002VB, BioTRADING, Netherlands) to final concentrations as detailed in **Table 1**. Samples
64 were kept on ice during workup to prevent RNA degradation as much as possible.

65 *Surrogate clinical sample panel*

66 Analytical performance of the SARS-CoV-2 and hRNaseP Primers and Probes, incl RT-PCR Chemistry
67 2× detection assay (cat. no. 50007, MBS, Netherlands) was determined using the SARS-CoV-2
68 Analytical Q Panel 01 (cat. no. SCV2AQP01-A, Qnostics Ltd, United Kingdom) described in **Table 2**.
69 In addition to background human cells, the samples in this panel contain inactivated SARS-CoV-2 viral
70 particles in transport medium of varying viral load. These samples thus closely mimic and are
71 representative of human clinical samples as stated in manufacturer's product description. Qnostics
72 samples were thawed on ice and 4µl of each sample was directly pipetted in a 96x20µl MBS microplate
73 in triplicate. Limit of detection (LOD) was determined by identification of the sample with the lowest
74 concentration of viral copies that still produced a fluorescent signal higher than the negative control
75 sample (SCV2AQP01-S09) in 3/3 replicates.

76 *Nasopharyngeal swabs*

77 A total of 101 individuals with suspected SARS-CoV-2 infection were sampled at the Canisius
78 Wilhelmina Hospital (Nijmegen, The Netherlands) using Σ -Transwab® nasopharyngeal swabs (Copan
79 Diagnostics, Italy). After collection, swabs were directly transferred to a sterile microtube containing
80 1mL AMIES liquid and heat-inactivated at 100°C for 10 minutes. An aliquot was taken from the tube
81 containing the swab and subjected to RNA extraction followed by qPCR measurements (reference
82 method), and the remaining volume was shipped to our laboratory in Goes where it was subjected to
83 direct RT-PCR as described below approximately 24-48h after primary sampling.

84 **Polymerase chain reactions**

85 *NextGenPCR direct RT-PCR method*

86 Our SARS-CoV-2 direct RT-PCR method using the NextGenPCR thermal cycler (MBS, The
87 Netherlands) is based on multiplex RT-PCR amplification of three target sequences followed by end-
88 point detection of amplicon-specific probe fluorescence to determine the presence of SARS-CoV-2

89 gRNA and human gDNA material in a sample. In the reaction, FAM-labelled (fluorescein amidites)
90 oligonucleotide probes are used to detect SARS-CoV-2 N1 and ORF1ab gene sequences and Cy5-
91 labeled oligonucleotide probes are used to detect a sequence in the human RPP30 gene. Primers/probes
92 specific for RPP30 were included as an internal control target, serving both to confirm absence of PCR
93 inhibition and indicate the presence of human genomic material in sample wells, aiding laboratory
94 personnel to verify that sampling and pipetting went correctly. Primer and probe oligonucleotide
95 sequences were designed using extensive bioinformatical analyses and in silico digital PCR to minimize
96 amplification of off-target sequences and formation of primer-dimers or other secondary structures.
97 Cross-reactivity of the reagents with other respiratory viruses was evaluated and showed no
98 amplification of targets in off-target organism genomic sequences (data not shown). A total of 16µl of
99 RT-PCR master mix containing 10µl RT-PCR Chemistry 2x, 1.6µl SARS-CoV-2/hRNaseP Primers and
100 Probes and 4.4µl nuclease-free H₂O (MBS, Netherlands) was added to 4µl of sample resulting in a total
101 reaction volume of 20µl. The microplate was heat-sealed after pipetting with a transparent Clear Heat
102 Seal (MBS, Netherlands) on a NextGenPCR Semiautomatic Heat Sealer (MBS, Netherlands) and
103 transferred to a NextGenPCR machine for thermal cycling using the RT-PCR program detailed in **Table**
104 **3**. Three wells containing Human Positive Control material from the MBS detection assay were
105 included to confirm efficient PCR cycling. After PCR was completed, the sealed microplate was
106 snapped to an imaging anvil (MBS, Netherlands), transferred to a FLUOstar Omega Microplate Reader
107 (BMG Labtech, Germany), scanned and fluorescence readout results exported to Excel for downstream
108 data analysis. For measurements in synthetic RNA, the microplate was also scanned on a Bio-1000F
109 Gel Imager (Microtek, Taiwan) and the results interpreted using custom designed QuickDetect software
110 (MBS, Netherlands).

111 *Reference qPCR method*

112 The SARS-CoV-2 qPCR detection method described by Corman and colleagues⁴ was used as the
113 reference method for this study. In short, nucleic acids were extracted from the sample/AMIES mixture
114 using a MagNA Pure 96 DNA And Viral NA Small Volume Kit on a MagNA Pure 96 Instrument (both
115 Roche Diagnostics GmbH, Mannheim, Germany) according to manufacturer's instructions. Using Xiril

116 robotic workstations (Roche Diagnostics GmbH, Mannheim, Germany), an internal control sequence
117 specific for phocine distemper virus (PhDV) was added to the sample prior to nucleic acid extraction.
118 After extraction, 5 μ l TaqMan Fast Virus 1-Step Master Mix (ThermoFisher Scientific) and 5 μ l primers
119 and probes (**Table 4**) were added to 10 μ l of spiked-in sample. Thermal cycling was performed on a
120 LC480-II instrument (Roche) using the RT-PCR program detailed in **Table 3**. Data analysis was
121 performed using FLOW software (Roche) and a threshold Ct-value of 40 was used as cut-off to interpret
122 results as positive ($Ct \leq 40$), negative (no Ct after 50 cycles) or indeterminate (Ct between 40-50).

123 Results

124 **Direct RT-PCR on synthetic RNA dissolved in water or AMIES liquid shows similar** 125 **amplification linearity and limit of detection**

126 We first determined the analytical sensitivity of our assay in a serial logarithmic dilution series of
127 synthetic RNA (**Table 1**). Samples were diluted in nuclease-free water to establish a baseline reading,
128 as well as AMIES liquid to detect possible discrepancies of the fluorescence readouts using an actual
129 VTM. A sample was called as being detected when all three replicates showed a significantly higher
130 fluorescence level (sample RFU \geq mean RFU in NTC + 3 \times standard deviation) as compared to
131 background signal in non-template control (NTC) wells within the same medium.

132 Using the above cut-offs, FAM fluorescence was detected on a Bio-1000F blue light scanner in
133 synthetic RNA dilutions ranging from 1 to 10,000 SARS-CoV-2 copies/ μ l in both solvents, but not in
134 the 0.1 copies/ μ l sample (**Figure 1A**). Dilutions made in nuclease-free H₂O as compared to AMIES
135 liquid were shown to have slightly higher R²-values (R² = 0.91 and R² = 0.87 in nuclease-free water
136 and AMIES liquid, respectively) as well as a higher signal amplitude when measured on a FLUOstar
137 Omega microplate reader, most noticeable in samples with a SARS-CoV-2 concentration \geq 100
138 copies/ μ l (**Figure 1B**). The FLUOstar Omega is equipped with multiple single channel fluorescent
139 detectors allowing for qualification of FAM signals as well as CY5 signals, the latter of which cannot
140 be detected with a Bio-1000F blue light scanner. Human *RPP30* was detected in the kit positive control
141 only ($p < 0.05$, two-sided Student's t-test), indicating that the used primer oligonucleotides are specific

142 for the intended *RPP30* human genomic target without off-target amplification in samples lacking
143 *RPP30* templates (**Figure 1C**).

144 **Direct RT-PCR on a panel of surrogate clinical samples provides accurate and sensitive** 145 **SARS-CoV-2 detection without prior nucleic acid extraction**

146 Next, a commercially available analytical sample panel containing samples with a known concentration
147 of inactivated SARS-Cov-2 particles (ranging from 1×10^6 to 5×10^1 copies per milliliter of sample)
148 mixed with a human cell matrix was tested using the direct RT-PCR protocol (**Table 2**). SARS-CoV-2
149 targets were detected in samples SCV2AQP01-S01 through SCV2AQP01-S05 indicating a limit of
150 detection of ≤ 1 copies/ μ l sample (**Figure 2A**). One out of three replicates in sample SCV2AQP01-S06
151 were detected and SARS-CoV-2 targets were not detected in samples SCV2AQP01-S07 through
152 SCV2AQP01-S09. The internal *RPP30* control target was detected in every well, confirming presence
153 of human genomic DNA in all samples (**Figure 2B**). The data showed a linear decrease in abundance
154 of fluorescence of SARS-CoV-2 targets with decreasing viral load in the sample set ($R^2 = 0.89$, data
155 not shown).

156 **Direct RT-PCR demonstrates high clinical sensitivity, specificity and sample calling** 157 **agreement as compared to reference qPCR methodology**

158 Finally, clinical sensitivity and specificity were determined using direct RT-PCR on 87 nasopharyngeal
159 swab samples that were identified as positive or negative for SARS-CoV-2 with a reference qPCR
160 method targeting the *E* gene that is recommended to use as a first-line screening tool in the original
161 article describing the method⁴. Of these samples, 64 were tested positive and 23 were tested negative
162 for SARS-CoV-2. As additional controls, we included 17 non-template controls (NTC) with only
163 AMIES viral transport medium as input, 6 non-template controls with only H₂O as input and 3 positive
164 controls containing plasmid SARS-CoV-2 *NI* sequences only.

165 SARS-CoV-2 target sequences were detected in 64/64 positive samples and 1/23 negative samples,
166 while *RPP30* sequences were detected in 85/87 samples corresponding to a false negative detection rate
167 of 2.3% for *RPP30* detection in clinical samples (**Figure 4A**). Both samples with undetectable *RPP30*

168 were positive for SARS-CoV-2 and were likely undetected due to competition for PCR reagents
169 between primer sets, a phenomenon that is well described in multiplex PCR which we could also
170 observe here (see **Figure 2**, reduced CY5 label fluorescence in samples with high SARS-CoV-2 copy
171 number). We observed strong correlation between fluorescence readouts following direct RT-PCR and
172 threshold cycle (C_t) numbers with a correlation coefficient of $R^2 = 0.84$ and concordance statistic of ρ_c
173 $= 0.79$ between the two techniques (**Figure 3**). A clinical agreement study was carried out to estimate
174 percent positive agreement (PPA, or clinical sensitivity) and percent negative agreement (NPA, or
175 clinical specificity) scores as recommended by the FDA in the “CLSI EP12: User Protocol for
176 Evaluation of Qualitative Test Performance” protocol. As detailed in **Figure 4B**, PPA was calculated
177 at 98.5% and NPA was calculated at 100%.

178 **Direct RT-PCR on an additional 14 clinical samples positive for respiratory viruses other** 179 **than SARS-CoV-2 confirms NextGenPCR primer-probe specificity**

180 To confirm analytical specificity of the used primer and probes in the NextGenPCR direct RT-PCR
181 method, 14 additional clinical specimens with varying respiratory viral infections other than SARS-
182 CoV-2 (see **Table 5**) were analyzed on a BioRad CFX96 qPCR system in addition to NextGenPCR
183 analysis as described above. No off-target amplification of FAM-labeled fragments was observed in
184 these samples (CT undetermined on CFX96, NextGenPCR RFU ranging from ~16,000 to 20,000 in the
185 FAM channel with a signal of 18,000 RFU in the negative SPEC0004 sample), except for three samples
186 where 400 copies/ μ l of MBS SARS-CoV-2/RPP30 positive control material was spiked-in prior to
187 sample workup to control for potential PCR inhibition due to buffer components (**Figure 5**). The signal
188 amplitude in the spike-in samples averaged to 142,707 RFU in the FAM channel, well above the average
189 FAM signal (RFU 76,667) in the 64 positive samples described above.

190 **Discussion**

191 The development of screening and diagnostic tools to detect SARS-CoV-2 sequences in clinical
192 specimens is of global importance. To reduce overall runtime and increase sample throughput, a
193 substantial number of publications describe the use direct RT-PCR testing in primary clinical samples

194 without prior nucleic acid extraction^{5, 6}. In this paper, we describe the use of the NextGenPCR SARS-
195 CoV-2 detection chemistry and NextGenPCR thermal cycler to accurately detect SARS-CoV-2 RNA
196 in clinical samples with significantly reduced PCR cycling time and without the need for sample lysis
197 or nucleic acid extraction. The analytical sensitivity of our developed assay was determined at 1.0×10^0
198 copies/ul. The same limit of detection was observed using direct RT-PCR in the Qnostics sample panel,
199 confirming that clinical samples with a SARS-CoV-2 viral load of ≥ 1 copy/ul can be consistently
200 detected in our assay. When compared to a reference quantitative RT-PCR method targeting the SARS-
201 CoV-2 E gene, our assay accurately identified samples in which SARS-CoV-2 RNA sequences are
202 present as evidenced by the high clinical agreement scores between the two techniques (PPA = 98.5%
203 and NPA = 100%).

204 The choice for a multiplex dual probe design targeting the SARS-CoV-2 *ORF1AB* and *NI* targets with
205 the same fluorophore (FAM) and the human *RPP30* target with a second fluorophore (CY5) was made
206 based on several theoretical advantages. The main contribution of a dual amplicon detection setup is an
207 increased signal amplitude generated for the SARS-CoV-2 targets, since both amplicons contribute to
208 the fluorescent signal generated in the sample instead of one. Additionally, a dual probe design provides
209 strong analytical protection against sequence variation of the target sequences, which is relevant due to
210 the significant rate at which SARS-CoV-2 variants are detected in the general population⁷. Currently,
211 the capacity to detect SARS-CoV-2 has not been impacted by recently identified variants such as
212 B.1.1.7 (British) and B.1.351 (South Africa) since these variants contain mutations⁸ in the S gene and
213 our assay targets different sequences of the SARS-CoV-2 genome. It is essential that we and other assay
214 developers stay vigilant in variant surveillance due to fast and frequent mutation of SARS-CoV-2 and
215 ensure that SARS-CoV-2 sequence detection capacity does not deteriorate as time progresses due to
216 mutational drift. To optimize the efficacy of our assay, we opted for thermal lysis of NPS specimens at
217 98°C prior to RT-PCR based on previous reports where improved detection rates of *NI* target sequences
218 have been reported⁵ in a singleplex direct RT-PCR application. The beneficial effect of thermal lysis
219 was confirmed by a second study⁹ that compared five RT-PCR master mixes for SARS-CoV-2 detection
220 by multiplex RT-PCR describing improved detection rates of *NI* and *N2* target sequences after thermal

221 sample lysis at 98°C (81%) as compared to lysis at 65°C (56%) or no thermal lysis (52%) prior to RT-
222 PCR testing.

223 Apart from SARS-CoV-2 testing, the NextGenPCR thermal cycling system is also suitable for the
224 detection of other pathogens including other microorganisms (viruses, bacteria) and pathogenic genetic
225 variants in the human genome. Brons and colleagues¹⁰ describe the use of NextGenPCR for fast
226 detection of multiple uropathogenic *Escherichia coli* strains in urinary tract infection patients in 52
227 minutes, significantly lowering the turnaround time over currently used techniques.

228 Concluding remarks

229 In summary, we here present a screening method for the detection of SARS-CoV-2 viral particles in
230 human clinical material through direct RT-PCR. Owing to ultrafast thermal cycling capacity, the
231 NextGenPCR system may aid to reduce the typical turnaround time of sample to result from ~4-6 hours
232 in conventional RT-PCR to ~45 minutes with NextGenPCR (RT-PCR cycling time of 27 minutes).
233 With lower TAT an overall increased laboratory throughput of sample tests can be achieved
234 characterized by a high level of analytical accuracy. This makes NextGenPCR highly suitable for large-
235 scale screening applications that may benefit public spaces where many individuals are tested for
236 SARS-CoV-2.

237 Acknowledgements

238 We would like to thank Martin Donker (Isogen Life Sciences B.V., Netherlands) for kindly providing
239 an aliquot of the SARS-CoV-2 Analytical Q Panel 01.

240 References

- 241 1. Zhu, N. et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J*
242 *Med* **382**, 727-733 (2020).
- 243 2. Coronaviridae Study Group of the International Committee on Taxonomy of, V. The species
244 Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it
245 SARS-CoV-2. *Nat Microbiol* **5**, 536-544 (2020).
- 246 3. Buller, R.S. Molecular detection of respiratory viruses. *Clin Lab Med* **33**, 439-60 (2013).
- 247 4. Corman, V.M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.
248 *Euro Surveill* **25** (2020).


- 249 5. Smyrlaki, I. et al. Massive and rapid COVID-19 testing is feasible by extraction-free SARS-
250 CoV-2 RT-PCR. *Nat Commun* **11**, 4812 (2020).
- 251 6. Cameron, A., Pecora, N.D. & Pettengill, M.A. Extraction-Free Methods for the Detection of
252 SARS-CoV-2 by Reverse Transcription-PCR: a Comparison with the Cepheid Xpert Xpress
253 SARS-CoV-2 Assay across Two Medical Centers. *J Clin Microbiol* **59** (2021).
- 254 7. Rice, A.M. et al. Evidence for Strong Mutation Bias toward, and Selection against, U Content
255 in SARS-CoV-2: Implications for Vaccine Design. *Mol Biol Evol* **38**, 67-83 (2021).
- 256 8. Pillay, T.S. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein.
257 *J Clin Pathol* **73**, 366-369 (2020).
- 258 9. Byrnes, S.A. et al. Multiplexed and Extraction-Free Amplification for Simplified SARS-CoV-
259 2 RT-PCR Tests. *Anal Chem* **93**, 4160-4165 (2021).
- 260 10. Brons, J.K. et al. Fast identification of Escherichia coli in urinary tract infections using a
261 virulence gene based PCR approach in a novel thermal cycler. *J Microbiol Methods* **169**,
262 105799 (2020).

263

264

265 Figures & legends


266 Figure 1



267

268 *Figure 1. Analytical sensitivity of the NextGenPCR SARS-CoV-2 detection assay as determined in a*
 269 *serial logarithmic dilution series of synthetic SARS-CoV-2 RNA. (A) Image of the microplate generated*
 270 *by a blue-light imager show clear distinction between samples with FAM fluorescence and samples*
 271 *without fluorescence. (B) Relative fluorescence units (RFU) measured on the FLUOstar Omega plate*
 272 *reader follows a linear profile with decreasing concentrations of synthetic RNA. Whiskers represent*
 273 *standard error of mean. (C) RPP30 is only detected in the positive control and not in synthetic RNA*
 274 *samples.*


275 **Figure 2**



276

277 *Figure 2. Fluorescence values for samples SCV2AQP01-S01 through SCV2AQP01-S09 of the Qnostics*
278 *validation sample panel measured in triplicate. (A) ORF1ab and NI (SARS-CoV-2 targets) are detected*
279 *through FAM-labeled probes and (B) human RPP30 (internal control) is detected through a CY5-*
280 *labeled probe. Bars represent mean relative fluorescence units (RFU), whiskers indicate standard error*
281 *of mean.*


282 **Figure 3**



283

284 *Figure 3. Comparison of the experimental NextGenPCR detection method versus an established qPCR*
285 *reference method. Fluorescence levels detected by the experimental method show a linear correlation*
286 *with Ct-values and show a distinct difference between positive and negative samples.*

287 **Figure 4**




288

289 *Figure 4. Distribution of fluorescence signals of the SARS-CoV-2 targets (y-axis) and RPP30 target (x-*
 290 *axis) for all included samples. Cut-off values are provided for positive SARS-CoV-2 signals (horizontal*
 291 *black line, RFU [640-680] = 1436) and positive RPP30 signals (vertical black line, RFU [485-520] =*
 292 *9985).*

293

294 **Figure 5**



295

296 *Figure 5. Relative fluorescence units (RFU) measured in the FAM channel for SARS-CoV-2 targets in*
297 *clinical samples with a respiratory viral infection other than SARS-CoV-2. Blue bars represent clinical*
298 *specimens, gray bars represent control samples. Samples SPEC0001, SPEC0011 and SPEC0013 were*
299 *spiked (-sp) with MBS positive control plasmids to a final concentration of 400 copies/ μ l.*

300

301 Tables

302 *Table 1. Synthetic RNA dilution scheme.*

Sample name	Target concentration (copies/ μ l)	Dilution medium
R1 H	1×10^4	Nuclease free H ₂ O
R2 H	1×10^3	Nuclease free H ₂ O
R3 H	1×10^2	Nuclease free H ₂ O
R4 H	1×10^1	Nuclease free H ₂ O
R5 H	1×10^0	Nuclease free H ₂ O
R6 H	1×10^{-1}	Nuclease free H ₂ O
R1 A	1×10^4	AMIES transfer medium
R2 A	1×10^3	AMIES transfer medium
R3 A	1×10^2	AMIES transfer medium
R4 A	1×10^1	AMIES transfer medium
R5 A	1×10^0	AMIES transfer medium
R6 A	1×10^{-1}	AMIES transfer medium

303

304 *Table 2. Sample description and viral content in the SARS-CoV-2 Analytical Q Panel 01.*

Sample name	Target concentration (dC/ml)
SCV2AQP01-S01	1,000,000
SCV2AQP01-S02	100,000
SCV2AQP01-S03	10,000
SCV2AQP01-S04	5,000
SCV2AQP01-S05	1,000
SCV2AQP01-S06	500
SCV2AQP01-S07	100
SCV2AQP01-S08	50
SCV2AQP01-S09	0

305

306 *Table 3. NextGenPCR reverse transcriptase RT-PCR and qPCR cycling programs.*

Program step	NextGenPCR			qPCR (LC480-II)		
	Cycle no.	Temp. (°C)	Time (s)	Cycle no.	Temp. (°C)	Time (s)
Reverse transcription	1	55	300	1	50	300
		98	60		95	20
Initial amplification	5	98	10	No initial amplification		
		60	20			
		72	3			
Amplification	45	98	5	45	95	3
		60	12		60	30
		72	3			
Total time (s)	1425			3597		

307

308 *Table 4. Primers used in the reference qPCR SARS-CoV-2 detection method.*

Name	Target	Oligonucleotide sequence	Final conc. (µM)
E_Sarbeco F	E gene	5'-ACAGGTACGTTAATAGTTAATAGCGT-3'	2
E_Sarbeco R	E gene	5'-ATATTGCAGCAGTACGCACACA-3'	2
E_Sarbeco P1	E gene	5'-/FAM/-ACACTAGCCATCCTTACTGCGCTTCG-/BHQ1/-3'	0.8
PhDVFwd1	PhDV	5'-GGTGGGTGCCTTTTACAAGAAC-3'	2
PhDVRev1	PhDV	5'-ATCTTCTTTCCTCAACCTCGTCC-3'	2
PhDVProbeCy5	PhDV	5'-/Cy5/-ATGCAAGGGCCAATTCTTCCAAGTT-/BHQ2/-3'	0.4

309

310

311 *Table 5. NextGenPCR assay specificity analysis of 14 patient samples with different respiratory virus*
 312 *infections other than SARS-CoV-2. RSV indicates respiratory syncytial virus; InfA, influenza A; InfB,*
 313 *influenza B; HMPV, human metapneumovirus; EV, enterovirus; AV, adenovirus; SARS-CoV-2, severe*
 314 *acute respiratory syndrome coronavirus 2. MBS positive control (400 copies/ μ l) was used as spike-in*
 315 *(-sp) for samples 1, 11 and 13.*

Sample	Pathogen	LC480-II	CFX96		NextGenPCR	
		C _T -pathogen	C _T -FAM	C _T -CY5	RFU-FAM	RFU-CY5
SPEC0001	RSV	29.93	NA	26.12	16834	19084
SPEC0002	InfB	35.65	NA	23.33	17958	19733
SPEC0003	RSV	23.95	NA	26.7	17010	19502
SPEC0004	None	NA	NA	21.33	18006	20542
SPEC0005	RSV	38.18	NA	24.67	17446	18850
SPEC0006	InfB	35.75	NA	26.09	18943	21102
SPEC0007	InfB	33.16	NA	26.89	18821	20435
SPEC0008	InfA	25.32	NA	20.54	19431	20510
SPEC0009	InfA	24.3	NA	25.04	17676	20674
SPEC0010	InfA	23.96	NA	22.2	17947	21715
SPEC0011	HMPV	31.18	NA	23	17506	19973
SPEC0012	HMPV	34.38	NA	21.84	17862	20455
SPEC0013	EV	21	NA	30.93	17498	20288
SPEC0014	AV	35	NA	21.88	20190	20559
SPEC0001-sp	RSV + SARS-CoV-2	NA	30.31	27.23	145080	18762
SPEC0011-sp	HMPV + SARS-CoV-2	NA	29.67	29.58	157763	19984
SPEC0013-sp	EV + SARS-CoV-2	NA	29.91	24.35	133763	18628
MBS_POS	SARS-CoV-2	NA	29.19	28.87	142544	17220
MBS_POS	SARS-CoV-2	NA	29.01	29.25	147992	18038
MBS_POS	SARS-CoV-2	NA	28.32	28.62	137585	15775
NTC	None	NA	NA	NA	13740	1044
NTC	None	NA	NA	NA	13884	986
NTC	None	NA	NA	NA	13593	977

316